¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"optimum point of coagulation"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
¿µ¹® coagulation ÇÑ±Û ÀÀ°í
¼³¸í   
  ¾×ü¹°ÁúÀ» °íü·Î º¯È­½Ã۴ °Í.
¿µ¹® coagulation necrosis ÇÑ±Û ÀÀ°í±«»ç
¼³¸í   
  ¼¼Æ÷ÀÇ Á×À½À» ³ªÅ¸³»´Â ÇüÅÂÇÐÀû º¯È­·Î¼­ ±«»çºÎÀ§°¡ ÀÀ°íÇÑ »óÅ·ΠÀִ °Í. ±«»ç¼¼Æ÷´Â È£»ê¼º µ¢¾î¸®·Î º¸À̸ç Àû¾îµµ ¼öÀϰ£ ¼¼Æ÷ÀÇ ±âº» À±°ûÀÌ º¸Á¸µÇ±â ¶§¹®¿¡ Á¶Á÷±¸Á¶¸¦ ½Äº°ÇÒ ¼ö ÀÖ´Ù. ´ëÇ¥ÀûÀ¸·Î ÇãÇ÷±«»ç¸¦ µé ¼ö ÀÖ´Ù. °æ»ö°ú ÇãÇ÷¿¡ ÀÇÇÑ Àú»ê¼ÒÁõ½Ã ½ÉÀå±ÙÀ̳ª ÄáÆÏ¿¡¼­ °üÂûµÇ°Å³ª Àü±â ¹× ¼öÀºÁßµ¶½Ã ÄáÆÏÀÇ ¿ä¼¼°ü¿¡¼­ °üÂûµÇ´Â °ÍÀ¸·Î ´Ü¹éÀÇ º¯¼º ÈÄ ³²¾ÆÀֱ⠶§¹®ÀÌ´Ù. ¼¼Æ÷ÀÇ À±°ûÀÌ ³²¾Æ À־ø·¡ Á¶Á÷ÀÇ ±¸Á¶¸¦ ÇüÅÂÇÐÀûÀ¸·Î ÀνÄÇÒ ¼ö Àִ °ÍÀ̠Ư¡ÀÌ´Ù.
¿µ¹® coagulation time ÇÑ±Û ÀÀ°í½Ã°£
¼³¸í   
  Ç÷¾×ÀÀ°í¶õ ÁöÇ÷ÀÇ ÇÑ °úÁ¤À¸·Î ¼¶À¯¼Ò¶õ ¹°ÁúÀ» ¸¸µé¾î ³»´Â °úÁ¤ÀÌ´Ù. ÀÌ ¼¶À¯¼Ò¶õ ¹°ÁúÀº ¼Õ»óµÈ Ç÷°üÀÇ ºÎÀ§¿¡ ÀÛ¿ëÇÏ¿© ¿©·¯ °¡Áö ¼¼Æ÷µéÀ» ¾ô¾î ¹­´Â ¿ªÇÒÀ» ÇÏ¿© °á±¹ ¼Õ»óµÈ Ç÷°ü¿¡¼­ Ç÷¾×ÀÇ ¼Ò½ÇÀ» ¸·´Â´Ù. Ç÷¾×ÀÀ°í´Â ´ÙÀ½°ú °°Àº 3´Ü°è·Î ÀÌ·ç¾îÁø´Ù.
  
  Ã¹¹øÂ° ´Ü°è´Â Ç÷°ü¼Õ»ó¿¡ ÀÇÇØ¼­ prothrombin activator¶ó´Â °ÍÀÌ ¸¸µé¾îÁö´Â ´Ü°èÀÌ´Ù. µÎ¹øÂ° ´Ü°è´Â ÀÌ prothrombin activator¶ó´Â ¹°Áú¿¡ ÀÇÇØ¼­ Ç÷¾×¼Ó¿¡ Àִ ÇÁ·ÎÆ®·ÒºóÀ̶ó´Â ¹°ÁúÀÌ Æ®·ÒºóÀ̶ó´Â ¹°Áú·Î ¹Ù²î´Â ´Ü°èÀÌ´Ù. ¼¼¹øÂ° ´Ü°è´Â Æ®·ÒºóÀ̶ó´Â ¹°Áú¿¡ ÀÇÇØ¼­ ¼¶À¯¼Ò¿øÀ̶ó´Â ¹°ÁúÀÌ ¼¶À¯¼ÒÀ¸·Î ¹Ù²î´Â ´Ü°èÀÌ´Ù.
  
  ÀÀ°íÀÛ¿ëÀº Å©°Ô 2°¡Áö·Î ³ª´µ´Âµ¥, ¿ÜÀμº ÀÀ°íÀÎÀÚ¿Í ³»Àμº ÀÀ°íÀÎÀÚ°¡ ±×°ÍÀÌ´Ù. ¿ÜÀμº ÀÀ°íÀÎÀÚ¿Í ³»Àμº ÀÀ°íÀÎÀڴ °¢±â º°°³·Î ÀÛ¿ëÇÏÁö¸¸, °á±¹Àº ¸¶Áö¸· °úÁ¤¿¡¼­ Çϳª·Î ¸¸³ª¼­ ¼¶À¯¼Ò¿øÀ» ¼¶À¯¼Ò(ÀÀ°íÀÛ¿ëÀÇ ¸¶Áö¸· ´Ü°è¿¡ »ý¼ºµÇ¸ç ´Ü´ÜÇϰí Ç®¸®Áö ¾Ê´Â ¸ÅµìÀ» Çü¼ºÇÏ¿© ÁöÇ÷ÀÛ¿ëÀ» ¿Ï¼ºÇÑ´Ù)À¸·Î ¸¸µé¾î ÀÀ°íÀÛ¿ëÀ» ³ªÅ¸³½´Ù.
¿µ¹® blood clotting, blood coagulation ÇÑ±Û Ç÷¾×ÀÀ°í
¼³¸í   
  »ç¶÷ÀÇ ¸ö¿¡ »óó°¡ ³ª¼­ ÃâÇ÷ÀÌ ÀÖÀ» °æ¿ì¿¡ À̰ÍÀ» ¸·°í ÇǸ¦ ´õÀ̻󠳪Áö ¾Ê°Ô Çϴ °ÍÀ» ÁöÇ÷À̶ó°í ÇÑ´Ù. ÁöÇ÷ÀÇ °úÁ¤¿¡´Â Å©°Ô µÎ °¡Áö ´Ü°è°¡ ÀÖ´Ù. Ã¹¹øÂ° ´Ü°è´Â Ç÷¼ÒÆÇµéÀÌ »óó°¡ ³ª¼­ ¼Õ»óµÈ Ç÷°üÀÇ ºÎÀ§¸¦ ¸·´Â °ÍÀÌ´Ù. ÀÌ·¸°Ô Çϸ頿켱 Ç÷°üÀÇ ¼Õ»óºÎÀ§·Î ºÎÅÍ Çǰ¡ ³ª¿À´Â °ÍÀ» ¸·À» ¼ö°¡ ÀÖ´Ù. ´ÙÀ½ÀÇ ´Ü°è´Â »ó󸦠¸·°í Àִ Ç÷¼ÒÆÇÀ§¿¡ ¿©·¯ °¡Áö ¹°ÁúµéÀÌ ÀÛ¿ëÇØ¼­ ´õ¿í ´Ü´ÜÇϰԠÇÏ¿© »óó°¡ ³­ Ç÷°ü¿¡¼­ Çǰ¡ »õ´Â °ÍÀ» ¿µ±¸È÷ ¸·´Â °ÍÀÌ´Ù. ½±°Ô ¸»Çϸé Ç÷¼ÒÆÇÀº º®µ¹¿¡ ÇØ´çÇϴ °ÍÀÌ°í µÎ¹øÂ° °úÁ¤¿¡ Âü¿©Çϴ ¹°ÁúµéÀº ½Ã¸àÆ®¿¡ ÇØ´çÇϴ °ÍÀÌ´Ù. ÀÌ µÎ °úÁ¤ÀÌ ¿ÏÀüÇÒ °æ¿ì¿¡ ÁöÇ÷ÀÌ ¼øÁ¶·Ó°Ô ÀϾ´Ù. Ç÷¾×ÀÀ°í¶õ µÎ¹øÂ° ´Ü°è¸¦ ÁöĪÇϴ ¸»·Î½á ¸Å¿ì º¹ÀâÇÑ ´Ü°è¸¦ °ÅÄ¡´Â ¹ÝÀÀÀ¸·Î ¸¶Áö¸· ´Ü°è´Â ¼¶À¯¼Ò¶ó´Â ¹°ÁúÀÌ ¸¸µé¾îÁ®¼­ ÀÌ ¹°ÁúÀÌ Ç÷¼ÒÆÇ°ú ±× ¿ÜÀÇ ¼¼Æ÷¸¦ ´Ü´ÜÇϰԠ°íÁ¤½ÃÄÑ Çǰ¡ »óó³­ Ç÷°üÀ¸·Î »õ´Â °ÍÀ» ¸·´Â´Ù. À̰ÍÀ» °¡Àå °£´ÜÈ÷ ¼³¸íÇÏÀÚ¸é Å©°Ô ´ÙÀ½°ú °°Àº 3°¡Áö ´Ü°è·Î ÀÌ·ç¾îÁø´Ù.
  
  Ã¹¹øÂ° ´Ü°è´Â Ç÷°ü¼Õ»ó¿¡ ÀÇÇØ¼­ ÇÁ·ÎÆ®·Òºó È°¼ºÁ¦¶ó´Â °ÍÀÌ ¸¸µé¾îÁö´Â ´Ü°èÀÌ´Ù.
  
  µÎ¹øÂ° ´Ü°è´Â ÀÌ ÇÁ·ÎÆ®·Òºó È°¼ºÁ¦¶ó´Â ¹°Áú¿¡ ÀÇÇØ¼­ Ç÷¾×¼Ó¿¡ Àִ ÇÁ·ÎÆ®·ÒºóÀ̶ó´Â ¹°ÁúÀÌ Æ®·ÒºóÀ̶ó´Â ¹°Áú·Î ¹Ù²î´Â ´Ü°èÀÌ´Ù.
  
  ¼¼¹øÂ° ´Ü°è´Â Æ®·ÒºóÀ̶ó´Â ¹°Áú¿¡ ÀÇÇØ¼­ ¼¶À¯¼Ò¿øÀ̶ó´Â ¹°ÁúÀÌ ¼¶À¯¼ÒÀ¸·Î ¹Ù²î´Â ´Ü°èÀÌ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • optimum
    1. ÃÖÀû-, ÀûÁ¤- 2. ÃÖÀûÁ¶°Ç
  • optimum allocation
    ÃÖÀû¹èºÐ
  • optimum dose
    1. ÀûÁ¤¿ë·® 2. ÀûÁ¤¼±·®
  • optimum temperature
    ÃÖÀû¿Âµµ
  • activated coagulation time
    Ȱ¼ºÇ÷¾×ÀÀ°í½Ã°£
  • blood coagulation
    Ç÷¾×ÀÀ°í
  • blood coagulation mechanism
    Ç÷¾×ÀÀ°í±âÀü
  • blood coagulation test
    Ç÷¾×ÀÀ°í°Ë»ç
  • coagulation
    ÀÀ°í
  • coagulation disorder
    ÀÀ°íÀå¾Ö
  • coagulation factor
    ÀÀ°íÀÎÀÚ
  • coagulation factor inhibitor
    ÀÀ°íÀÎÀÚ¾ïÁ¦Á¦
  • coagulation necrosis
    ÀÀ°í±«»ç
  • coagulation pathway
    ÀÀ°í°æ·Î
  • coagulation time
    ÀÀ°í½Ã°£
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • optimum dose
    ÀûÁ¤¿ë·®, ÀûÁ¤¼±·®
  • optimum
    ÃÖÀû, ÁöÀû
  • coagulation
    ÀÀ°í
  • disseminated intravascular coagulation
    ÆÄÁ¾Ç÷°ü³»ÀÀ°í
  • coagulation V factor
    Á¦5Ç÷¾×ÀÀ°íÀÎÀÚ
  • blood coagulation mechanism
    Ç÷¾×ÀÀ°í±âÀü
  • coagulation necrosis
    ÀÀ°í±«»ç
  • blood coagulation test
    Ç÷¾×ÀÀ°í°Ë»ç
  • coagulation time
    ÀÀ°í½Ã°£
  • point mutation
    Á¡µ¹¿¬º¯ÀÌ
  • point
    Á¡
  • blind point
    ¸ÍÁ¡
  • critical point
    ÀÓ°èÁ¡
  • near point
    ±ÙÁ¡
  • reference point
    ±âÁØÁ¡
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • optimum allocation
    ÃÖÀû¹èºÐ
  • optimum cure
    ÃÖÀûÄ¡·á
  • optimum dose
    ÀûÁ¤¿ë·®, ÀûÁ¤¼±·®
  • optimum estimate
    ÃÖÀûÃßÁ¤°ª
  • optimum
    ÃÖÀû, ÁöÀû
  • optimum temperature
    ÃÖÀû¿Âµµ
  • activated coagulation time
    Ȱ¼ºÇ÷¾×ÀÀ°í½Ã°£
  • blood coagulation
    Ç÷¾×ÀÀ°í
  • blood coagulation mechanism
    Ç÷¾×ÀÀ°í±âÀü
  • blood coagulation test
    Ç÷¾×ÀÀ°í°Ë»ç
  • coagulation
    ÀÀ°í
  • coagulation disorder
    ÀÀ°íÀå¾Ö
  • coagulation factor
    ÀÀ°íÀÎÀÚ
  • coagulation necrosis
    ÀÀ°í±«»ç
  • coagulation pathway
    ÀÀ°í°æ·Î
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • point to point correspondence
    Á¡´ëÁ¡´ëÀÀ(ïÇÓßïÇÓßëë).
  • activated coagulation time(ACT)
    Ȱ¼º Ç÷¾× ÀÀ°í½Ã°£
  • activated coagulation time=ACT
    Ȱ¼ºÈ­ ÀÀ°í½Ã°£
  • anti-inhibitor coagulation complex
    Ç×¾ïÁ¦Á¦ÀÀ°í°áÇÕü
  • hereditary coagulation disorder
    À¯Àü¼º ÀÀ °íÀå¾Ö.
  • plasma coagulation factor
    Ç÷ÀåÀÀ°íÀÎÀÚ
  • J point
    J Á¡(ïÇ)
  • NPA->near point of accommodation
    Á¶Àý±ÙÁ¡
  • NPC->near point of convergence
    ´«¸ðÀ½±ÙÁ¡, ÆøÁÖ±ÙÁ¡
  • Wilkerson point system
    ÀªÄ¿½¼Á¡¼öü°è
  • alveolar point =prosthion
    Ä¡Á¶Á¡(¡­ïÇ).
  • apex beat =point of maximum impulse
    ½É÷¹Úµ¿(ãýôÓÚÑÔÑ)
  • freezing point
    ¾î´ÂÁ¡(¡­ïÇ), ºù°áÁ¡(޼̿ïÇ), ÀÀ°íÁ¡(ëêͳïÇ).
  • freezing point depression
    ¾î´ÂÁ¡°­ÇÏ(¡­Ë½ù»).
  • freezing point depression
    ¾î´ÂÁ¡°­ÇÏ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • optimum point of coagulation
    ÃÖÀûÀÀÁýÁ¡ (Ì§ËøËôÌ¤Ëø).
  • optimum point of coagulation
    ÃÖÀûÀÀÁýÁ¡ (õÌîêëêó¢ïÇ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • point to point correspondence
    Á¡´ëÁ¡´ëÀÀ(ïÇÓßïÇÓßëë).
  • optimal dose ; optimum dose
    ÃÖÀû·®, ÀûÁ¤·®(îêïáåÖ).
  • optimal dose ; optimum dose
    ¹æ»ç [¾à¸®,ÇØºÎ,¿¹¹æ]ÃÖÀû·®, ÀûÁ¤·®(ËøËøËâ).
  • optimal dose ; optimum dose
    ÃÖÀû·®, ÀûÁ¤·®(îêïáåÖ).
  • optimum
    ÃÖÀû(õÌîê), ÁöÀû(ò¸îê).
  • optimum allocation
    ÃÖÀû¹èºÐ(õÌîêÛÕÝÂ).
  • optimum condition
    ÃÖÀû(õÌîê)Á¶°Ç
  • optimum cure
    ÃÖÀûÄ¡·á(õÌîêö½èþ).
  • optimum dose
    ÀûÁ¤·®(îêïáåÖ).
  • optimum effective temperature
    ÃÖÀû°¨°¢¿Âµµ(Ì§ËøË§Ë§Ëí̬).
  • optimum estimate
    ÃÖÀûÃßÁ¤·®(õÌîêõÏïÒåÖ).
  • optimum force
    ÃÖÀûÀÀ·Â(õÌîêëëæ³).
  • optimum position
    ÃÖÀûÀ§Ä¡(õÌîêêÈöÇ).
  • optimum position
    ÃÖÀûÀ§Ä¡(ÃÖÀûÀ§Ä¡).
  • optimum proportion
    ÃÖÀûºñ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • optimum pH
    ÃÖÀû(õÌîê) pH
  • optimum temperature
    ÃÖÀû¿Âµµ(õÌîêè®Óø)
  • coagulation
    ÀÀ°í(ëêͳ)
  • extrinsic blood coagulation
    ¿ÜÀÎ Ç÷¾×ÀÀ°í (èâì×úìäûëêͳ)
  • intrinsic blood coagulation
    ³»ÀÎ Ç÷¾×ÀÀ°í(Ò®ì×úìäûëêͳ)
  • achromic point
    ¹«»öÁ¡(ÙíßäïÃ)
  • branch point
    ºÐÁöÁ¡(ÝÂò«ïÃ)
  • carbon dioxide compensation point
    ÀÌ»êȭź¼Ò º¸»óÁ¡(ì£ß«ûù÷©áÈÜÍßÁïÃ)
  • compensation point
    º¸»óÁ¡(ÜÍßÁïÃ)
  • critical point
    ÀÓ°èÁ¡ (×üÍ£ïÃ)
  • critical point drying
    ÀÓ°èÁ¡ °ÇÁ¶(×üÍ£ïÃËëðÏ)
  • crossover point
    ±³Â÷Á¡(Îßó©ïÃ)
  • end point
    Á¾¸»Á¡(ðûØÇïÇ)
  • end-point method
    Á¾¸»Á¡¹ý(ðûØÇïÇÛö)
  • end-point mutation
    Á¾¸»Á¡ º¯ÀÌ (ðûØÇïÇܨì¶)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • coagulation
    ÀÀ°í
  • optimum
    ÃÖÀû, ÁöÀû
  • central point artifact
    Áß½ÉÁ¡Àΰø¹°
  • cut-off point
    °áÁ¤Á¡
  • melting point
    À¶(ÇØ)Á¡, ³ì´ÂÁ¡
  • sylvian point
    ½Çºñ¿ì½ºÁ¡
  • umbilical point
    Á¦Á¡
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
DIC dicarbazine; differential interference contrast microscopy; diffuse intravascular coagulation; direc...
FP false positive; family physician; family planning; family practice; family practitioner; Fanconi pan...
BP Bachelor of Pharmacy; back pressure; barometric pressure; basic protein; bathroom privileges; bed pa...
PMI pain management inventory; past medical illness; patient medication instruction; perioperative myoca...
PPP pain perception profile; palatopharyngoplasty; palmoplantar pustulosis; pentose phosphate pathway; p...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ACT Activated Coagulation Time
APC Argon Plasma Coagulation
DIC Disseminated Intravascular Coagulation
DIC Disseminated intravascular coagulation syndrome
ILC Interstitial Laser Coagulation
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • nadir : the lowest point; point of greatest adversity or despair.

    nadisan

    ³ªµð»ê
    ¼ö»êÈ­ ⿬À¸·Î Æ÷È­ÇÑ ÁÖ¼®»ê Ä®·ý ⿬ÀÇ »óǰ¸í.
  • optimum
    ÁöÀû, ÃÖÀû
    1. ÀÛ¿ë°ú ±â´ÉÀ» ÀεµÇÏ´Â µ¥ °¡Àå ÀûÇÕÇÑ È¯°æ Á¶°Ç. 2. ÁÖ¾îÁø ȯ°æ ÇÏ¿¡¼­ °¡Àå ¹Ù¶÷Á÷ÇÑ ½ÄǰÀÇ ¾ç¿¡ ´ëÇÑ PirquetÀÇ ¿ë¾î.
  • optimum effective temperature
    ÃÖÀû °¨°¢ ¿Âµµ
  • optimum functional occlusion
    ±â´ÉÀû ÃÖÀû ±³ÇÕ
  • optimum ratio
    ÃÖÀûºñ
  • optimum sensitivity
    ÃÖÀû °¨µµ
  • activated coagulation time
    Ȱ¼º Ç÷¾× ÀÀ°í½Ã°£
  • anti-inhibitor coagulation complex
    Ç×¾ïÁ¦Á¦ ÀÀ°í °áÇÕü
  • bacterial coagulation
    ¼¼±Õ ÀÀÁý
  • blood coagulation
    Ç÷¾× ÀÀ°í
    µ¿ÀǾî=blood clotting. 1. Ç÷¾×ÀÇ ¸¹Àº ÀÀ°íÀÎÀÚ°¡ »óÈ£ÀÛ¿ëÇϰí ÇÕÃÄÁ®¼­ ÃÖÈÄ¿¡´Â ºÒ¿ë¼ºÀÇ ¼¶À¯¼Ò ±«ÀÇ Çü¼ºÀ» ÀÏÀ¸Å°´Â ¿¬¼ÓÀû ¹ÝÀÀÀÌ´Ù. 2. Ç÷¾×ÀÌ Ç÷°ü ¹ÛÀ¸·Î ³ª¿ÔÀ» ¶§ Á©¸®»óÀ¸·Î ±»¾îÁö´Â Çö»ó. À̰ÍÀº Ç÷¾× ¼Ó¿¡ ÇǺ기À̶ó°í ÇÏ´Â ½Ç ¸ð¾çÀÇ ¹°ÁúÀÌ ¼®ÃâµÇ¾î ±×¹° ¸ð¾çÀ¸·Î ¾ôÈ÷°í, ±× ¼Ó¿¡ Ç÷±¸¸¦ °¡µÎ¾î µÎ±â ¶§¹®ÀÌ´Ù. ÀÌ Ç÷±¸ µ¢¾î¸®´Â ½Ã°£ÀÌ Áö³²¿¡ µû¶ó Á¡Á¡ ¼öÃàÇÏ¿© ÀÛ¾ÆÁö¸é¼­ ´ãȲ»öÀÇ Åõ¸íÇÑ ¾×ü°¡ ½º¸ç ³ª¿Â´Ù. Ç÷±¸ÀÇ µ¢¾î¸®¸¦ Ç÷º´À̶ó Çϰí, ½º¸ç ³ª¿Â Åõ¸íÇÑ ¾×ü¸¦ Ç÷ûÀ̶ó°í ÇÑ´Ù. Ç÷¾× ÀÀ°í´Â »ý¸íÀ» À¯ÁöÇÏ´Â µ¥ ºÒ°¡°áÇÑ °ÍÀ¸·Î, ¸¸ÀÏ Ç÷¾×¿¡ ÀÌ ÀÛ¿ëÀÌ ¾øÀ¸¸é ÃâÇ÷¿¡ ÀÇÇÏ¿© °ð Á×°Ô µÈ´Ù. ÀÏ»ó»ýȰ¿¡¼­´Â ²÷ÀÓ¾øÀÌ ¿Ü»óÀ» ÀÔ°Ô µÇ°í ±×¶§ ´Ù¼Ò³ª¸¶ ¸ð¼¼Ç÷°üÀÌ ÆÄ¿­µÇ´Âµ¥, ÆÄ¼ÕºÎÀ§´Â Ç÷¾× ÀÀ°í¿¡ ÀÇÇÏ¿© ¼öº¹µÈ´Ù. Ç÷¾× ÀÀ°í°¡ ÀϾ´Â ¸ÞÄ¿´ÏÁò¿¡ ´ëÇØ¼­´Â ¸î °¡Áö ¼³ÀÌ ÀÖÁö¸¸ ¾î´À °ÍÀÌµç ±âº»ÀûÀ¸·Î´Â Ç÷¾×ÀÌ Ç÷°ü ¹ÛÀ¸·Î ³ª¿À¸é Ç÷¼ÒÆÇÀÌ ÆÄ±«µÇ¾î Æ®·Òº¸ÇÃ¶ó½ºÆ¾ÀÌ »ý±â°í, À̰ÍÀÌ Ç÷¾× ¼ÓÀÇ Ä®½· À̿°ú ÇÔ²² ÀÛ¿ëÇÏ¿© Ç÷Àå ´Ü¹éÁúÀÇ ÇϳªÀÎ ÇÁ·ÎÆ®·ÒºóÀ» Æ®·ÒºóÀ¸·Î º¯È­½ÃŲ´Ù. ÀÌ Æ®·ÒºóÀÌ ÇǺ긮³ë°Õ¿¡ ÀÛ¿ëÇÏ¿© ÇǺ기ÀÌ µÈ´Ù. ÀÌ °úÁ¤¿¡´Â Ç÷ÀåÀ̳ª Ç÷¼ÒÆÇ¿¡ ÀÖ´Â ¸¹Àº ÀÎÀÚ°¡ °ü¿©Çϴµ¥, ¿¬±¸ÀÚ¿¡ µû¶ó °¢¾ç°¢»öÀÇ À̸§À¸·Î ºÒ¸®¾î È¥¶õÀ» ÃÊ·¡Çϰí ÀÖÀ¸¹Ç·Î, ±¹Á¦Ç÷¾×ÀÀ°íÀ§¿øÈ¸¿¡¼­ À̵é ÀÎÀÚ¸¦ ¹øÈ£·Î ³ªÅ¸³»µµ·Ï °áÁ¤Çϰí ÀÖ´Ù. Á¦1»óÀÇ Æ®·Òº¸ÇÃ¶ó½ºÆ¾ÀÌ Çü¼ºµÇ´Â °úÁ¤ÀÌ °¡Àå º¹ÀâÇϰí, Ç÷¾× ÀÀ°í¿¡ °É¸®´Â ´ëºÎºÐÀÇ ½Ã°£ÀÌ ÀÌ °úÁ¤¿¡ ¼Ò¿äµÈ´Ù. Æ®·Òº¸ÇÃ¶ó½ºÆ¾ÀÌ ¸¸µé¾îÁö´Â µ¥´Â µÎ °¡Áö °æ·Î°¡ ÀÖ´Ù. óÀ½ °æ·Î´Â Ç÷°ü ¼Ó¿¡¼­ ÀÌ·ç¾îÁø´Ù. Ç÷Àå ¼Ó¿¡ À̹°Áú°ú Á¢Çϸé Ȱ¼ºÈ­µÇ´Â È¿¼Ò°¡ Àִµ¥, ÇöÀç Á¦ XIÀÎÀÚ¿Í Á¦ XIIÀÎÀÚÀÇ µÎ °¡Áö°¡ ¾Ë·ÁÁ® ÀÖ´Ù. À̰ÍÀÌ ¹æ¾Æ¼è°¡ µÇ¾î Á¦ VÀÎÀÚ, Á¦ VIIIÀÎÀÚ, Á¦ IXÀÎÀÚ µî°ú Ç÷¼ÒÆÇÀ¸·ÎºÎÅÍÀÇ ÀÎÀÚ°¡ ÀÛ¿ëÇÏ¿© Ç÷¾× Æ®·Òº¸ÇÃ¶ó½ºÆ¾ÀÌ »ý¼ºµÈ´Ù. ´Ù¸¥ ÇϳªÀÇ °æ·Î´Â Ç÷°ü ¹ÛÀÇ Á¶Á÷¿¡¼­ ÀÌ·ç¾îÁø´Ù. ÆÄ±«µÈ Á¶Á÷¿¡ Ç÷Àå ¼ÓÀÇ Á¦ VÀÎÀÚ, Á¦ VIIÀÎÀÚ, Á¦ XÀÎÀÚ µîÀÌ ÀÛ¿ëÇÏ¿© Á¶Á÷ Æ®·Òº¸ÇÃ¶ó½ºÆ¾ÀÌ »ý¼ºµÈ´Ù. Á¦2»óÀÇ Æ®·ÒºóÀÇ »ý¼º¿¡¼­´Â Ç÷¾× ¹× Á¶Á÷¿¡ »ý±ä Ȱ¼º Æ®·Òº¸ÇÃ¶ó½ºÆ¾ÀÌ Ä®½· À̿°ú ÇÔ²² Ç÷Àå ¼ÓÀÇ ÇÁ·ÎÆ®·Òºó¿¡ ÀÛ¿ëÇÏ¿© Æ®·ÒºóÀ» Çü¼ºÇÑ´Ù. ÇÁ·ÎÆ®·ÒºóÀº °£¿¡¼­ ºñŸ¹Î KÀÇ ÀÛ¿ëÇÏ¿¡ ¸¸µé¾îÁö°í, ÇìÆÄ¸°Àº ÀÌ Á¦ 2»óÀ» ¾ïÁ¦ÇÏ¿© Ç÷¾× ÀÀ°í ÀúÁö ÀÛ¿ëÀ» ³ªÅ¸³½´Ù. Á¦ 3»ó¿¡¼­´Â Æ®·ÒºóÀÌ ÇǺ긮³ë°ÕÀÇ ÆéƼµå °áÇÕÀ» ºÐÇØÇÏ¿© ÇǺ기 ¼¶À¯¸¦ ¼®Ãâ½ÃŲ´Ù. ¿©±â¿¡ Ä®½· À̿°ú ÇÔ²² Á¦ XIII ÀÎÀÚ°¡ ÀÛ¿ëÇÏ¿© ÇǺ기¸ÁÀ» ¸¸µé¾î Ç÷º´ÀÌ ¿Ï¼ºµÈ´Ù. ¿©±â¿¡¼­ »ý¼ºµÈ ÇǺ기Àº ±×´ë·Î µÎ¸é ´Ù½Ã ¿ëÇØµÇ´Âµ¥ À̰ÍÀ» ¼¶À¯¼Ò ¿ëÇØ¶ó°í ÇÑ´Ù. ÀÌ ¼¶À¯¼Ò ¿ëÇØ´Â Ç÷Àå ¼Ó¿¡ ÀÖ´Â Çö󽺹̳ë°ÕÀÌ È°¼ºÈ­ÇÏ¿© Çö󽺹ÎÀÌ µÇ°í ÇǺ기À» ³ìÀ̱⠶§¹®ÀÌ´Ù.
  • coagulation band
    ÀÀ°í´ë
    Weltmann ÀÀ°í ½ÃÇè¿¡¼­ Çü¼ºµÈ ÀÀ°í´ë.
  • coagulation factor
    ÀÀÇ÷ ÀÎÀÚ, ÀÀ°í ÀÎÀÚ
  • coagulation factor inhibitor
    ÀÀ°í ÀÎÀÚ ¾ïÁ¦Á¦
  • coagulation pathway
    ÀÀ°í °æ·Î
  • coagulation study
    ÀÀ°í °Ë»ç
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
optimum The best or most suitable; e.g., denoting the dose of a remedy likely to give most benefit with fewest side effects, the temperature or pH at which an enzyme has maximal activity.
Origin: L. Ntr. Sing. Of optimus, best
(05 Mar 2000)
optimum dose The dose of a drug or radiation that will produce the desired effect with minimum likelihood of undesirable symptoms.
(05 Mar 2000)
optimum pH <biochemistry> The pH at which an enzyme has maximum potency and efficiency.
(09 Oct 1997)
optimum temperature The temperature at which any operation, such as the culture of any special microorganism, is best carried on.
(05 Mar 2000)
blood coagulation The sequential process by which the multiple coagulation factors of the blood interact, ultimately resulting in the formation of an insoluble fibrin clot; it may be divided into three stages: stage 1, the formation of intrinsic and extrinsic prothrombin converting principle; stage 2, the formation of thrombin; stage 3, the formation of stable fibrin polymers.
(12 Dec 1998)
blood coagulation factor inhibitors Substances, usually endogenous, that act as inhibitors of blood coagulation. They may affect one or multiple enzymes throughout the process. As a group, they also inhibit enzymes involved in processes other than blood coagulation, such as those from the complement system, fibrinolytic enzyme system, blood cells, and bacteria.
(12 Dec 1998)
blood coagulation factors Endogenous substances, usually proteins, that participate in the blood coagulation process.
(12 Dec 1998)
blood coagulation tests Laboratory tests for evaluating the individual's clotting mechanism.
(12 Dec 1998)
coagulation 1. <haematology> The process of clot formation.
2. <chemistry> The solidification of a sol into a gelatinous mass, an alteration of a disperse phase or of a dissolved solid which causes the separation of the system into a liquid phase and an insoluble mass called the clot or curd. Coagulation is usually irreversible.
3. <surgery> The disruption of tissue by physical means to form an amorphous residuum, as in electrocoagulation and photocoagulation.
Origin: L. Coagulatio
(18 Nov 1997)
coagulation factor <haematology> Group of plasma protein substances (Factor I-XIII) contained in the plasma, which act in concert to bring about blood coagulation. Many of the factors contain EGF like domains.
(29 Sep 1997)
coagulation factor XI <haematology> A plasma serine protease with an apple domain.
(18 Nov 1997)
coagulation necrosis A type of necrosis in which the affected cells or tissue are converted into a dry, dull, fairly homogeneous eosinophilic mass without nuclear staining, as a result of the coagulation of protein as occurs in an infarct; microscopically, the necrotic process involves chiefly the cells, and remnants of histologic elements (e.g., elastin, collagen, muscle fibres) may be recognizable, as well as "ghosts" of cells and portions of cell membranes; may be caused by heat, ischemia, and other agents that destroy tissue, including enzymes that would continue to alter the devitalised cellular substance.
(05 Mar 2000)
coagulation profile A test which measures the speed of blood coagulation at different steps of the coagulation pathway.
(27 Sep 1997)
coagulation time The time required for blood to coagulate; prolonged in haemophilia and in the presence of obstructive jaundice, some anaemias and leukaemias, and some of the infectious diseases.
Synonym: clotting time.
(05 Mar 2000)
coagulation vitamin An obsolete term for vitamin K.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • coagulation
    ÀÀ°í(ÀÛ¿ë);ÀÀ°í¹°
  • optimum
    ÃÖ¼±ÀÇ
  • optimum
    ÃÖÀûÀÇ;ÃÖ¼±ÀÇ
  • optimum
    (¼ºÀå,¹ø½Ä µîÀÇ) ÃÖÀûÁ¶°Ç
  • point
    Á¡,³¡,¿äÁ¡,Áö½ÃÇÏ´Ù,ÁöÀûÇÏ´Ù
  • point-of-sale
    ¸ÅÀåÀÇ
  • point-of-sales
    ¸ÅÀåÀÇ
  • Curie point (temperature)
    Äû¸®Á¡(¿Âµµ)(Àڱ⠺¯Å°¡ ÀϾ´Â ¿Âµµ)
  • Point Four
    Á¦4Á¤Ã¥(Truman ´ëÅë·ÉÀÇ ¹Ì°³¹ß Áö¿ª °æÁ¦ ¿øÁ¶ Á¤Ã¥)
  • ball point pen
    º¼Ææ
  • black point
    Èæ¼öº´
  • boiling point
    ºñµîÁ¡
  • bradkeven point
    ä»êÁ¡
  • burning point
    ¹ßÈ­Á¡
  • cover point
    ÈÄÀ§
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á